Last reviewed · How we verify

Neurology Group of Bergen County, P.A. — Portfolio Competitive Intelligence Brief

Neurology Group of Bergen County, P.A. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Guanfacine (sustained release) Guanfacine (sustained release) marketed Alpha-2A adrenergic receptor agonist Alpha-2A adrenergic receptor Neurology / Psychiatry

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Children's Hospital Medical Center, Cincinnati · 1 shared drug class
  2. Research Foundation for Mental Hygiene, Inc. · 1 shared drug class
  3. Shire · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Neurology Group of Bergen County, P.A.:

Cite this brief

Drug Landscape (2026). Neurology Group of Bergen County, P.A. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/neurology-group-of-bergen-county-p-a. Accessed 2026-05-18.

Related